NEW YORK, Oct. 11, 2010 (GLOBE NEWSWIRE) -- Manhattan Pharmaceuticals, Inc. (OTCBB:MHAN) is scheduled to present at the Precision IR Biotech, Healthcare & Pharmaceutical Virtual Conference at 11:00 AM ET on Wednesday, Oct 13, 2010.
Dr. Malcolm Morville, Director of Manhattan Pharmaceuticals, will provide an overview of the company and its clinical development programs. The audio and slide presentation will be webcast and can be accessed by visiting the Manhattan Pharmaceuticals website at www.manhattanpharma.com.
About Manhattan Pharmaceuticals, Inc.
Manhattan Pharmaceuticals is a specialty healthcare product company focused on the development and commercialization of innovative treatments for underserved patient populations. The Company is currently focused on two lead programs: AST-726, a nasally delivered vitamin B12 remediation treatment, and Hedrin®, a novel, non-insecticide treatment for pediculosis (head lice), which is being developed through a joint venture with Nordic Biotech. The company is also studying AST-915 for the treatment of essential tremor and a topical GEL product which may be commercialized as an OTC treatment for mild psoriasis.
Note Regarding Forward-Looking Statements
This press release contains forward-looking statements regarding future events. Such statements are just predictions and are subject to risks and uncertainties that could cause the company's actual results to differ materially. These risks are described in greater detail in the company's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2009.
CONTACT: Manhattan Pharmaceuticals, Inc. Michelle Carroll, Vice President, Corporate Development (212) 582-3950
